MarketPeel
Insider Trading Intelligence
Pricing
…
JM

Jonathan Mcneill

DYN
SEE REMARKS · DYNE THERAPEUTICS, INC. · CIK 0001824673
FILING MIX · LIFETIME34%/66%
BUYS
24
SELLS
47
TOTAL VALUE
$6.68M
COMPANIES
2
ACTIVE SINCE
Sep 2020
HOLDINGS NOW
271,264
AVG SELL PX
$22.05
TRADE KIND
SHOWING 71 / 71
Trades · vs SPY
Loading price series…
Performance · forward returns vs SPY
34 backtested trades · 8 horizons · 2 pendingHow are these numbers computed? →
Forward-return performance of every backtestable P/S trade by Jonathan Mcneill, measured at 8 horizons from 7 days to 2 years. Deduped per economic event so co-filings count once. Excess return = trade return minus SPY return over the same window.
HORIZONTRADESWIN RATEINSIDER RETURNSPY RETURNMEAN EXCESSMEDIAN EXCESST-STAT
7d34+47.06%+2.68%+0.78%+1.91%+0.93%0.90
14d34+50.00%-0.10%+0.89%-1.00%+0.02%-0.42
30d34+41.18%+4.68%+2.81%+1.87%+2.63%0.47
60d34+44.12%+15.59%+3.51%+12.07%-0.42%1.91
90d34+32.35%+17.69%+5.26%+12.43%+8.36%1.82
180d34+32.35%+42.27%+10.90%+31.37%+24.38%2.65
1y34+58.82%+17.52%+18.30%-0.78%-42.79%-0.05
2y34(2 pending)+62.50%+2.93%+40.15%-37.22%-55.74%-3.92
How to read this: Insider Returnis the average raw return of the filer's trades over the horizon. SPY Return is what SPY did over those same windows — reference only, not a comparison. The headline alpha number is Mean Excess = Insider − SPY; green means the filer beat SPY, red means they trailed it. Win rate is the share of individual trades where the filer beat SPY. T-statvalues above 2 mean the alpha is unlikely to be chance given the sample size. "Pending" counts trades where the horizon hasn't elapsed yet; their stats are not included in the row average.
Holdings over time
DYN · 132,106 shares · as of Aug 19, 2024
057,796115,592173,388231,1842021202220232024SHARES HELD
Trading cadence · quarterly flow
BUY ● SELL ●
2020
2020
2021
2021
2021
2021
2022
2022
2022
2022
2023
2023
2023
2023
2024
2024
2024
2024
2025
2025
2025
2025
2026
2026
FLOW · 24 buys / 47 sellsCOVERAGE · 24 quarters
Form 4 filings · all activity
COMPANYTYPESHARESPRICEVALUEHELD AFTERTRADE DATEFILEDDETAILS
CBIO
CRESCENT BIOPHARMA, INC.
SALE10b5-1
10b5-1 plan
20,549$17.99$369.7K139,158Jun 22, 2026Jun 23, 2026 ↗View →
CBIO
CRESCENT BIOPHARMA, INC.
PURCHASEGRANT
Stock grant
19,507——153,707Dec 15, 2025Dec 17, 2025 ↗View →
CBIO
CRESCENT BIOPHARMA, INC.
PURCHASEGRANT
Stock grant
78,029——78,029Dec 15, 2025Dec 17, 2025 ↗View →
CBIO
CRESCENT BIOPHARMA, INC.
PURCHASEGRANT
Stock grant
6,000——159,707Dec 15, 2025Dec 17, 2025 ↗View →
CBIO
CRESCENT BIOPHARMA, INC.
PURCHASEGRANT
Stock grant
172,836——172,836Dec 8, 2025Dec 10, 2025 ↗View →
DYN
DYNE THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
2,400$45.01$108.0K132,411Aug 19, 2024Aug 20, 2024 ↗View →
DYN
DYNE THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
305$46.00$14.0K132,106Aug 19, 2024Aug 20, 2024 ↗View →
DYN
DYNE THERAPEUTICS, INC.
SALE
Chief Business Officer
1,823$31.34$57.1K134,811Jun 11, 2024Jun 11, 2024 ↗View →
DYN
DYNE THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
495$28.59$14.2K136,634May 16, 2024May 17, 2024 ↗View →
DYN
DYNE THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
2,279$28.20$64.3K137,129May 16, 2024May 17, 2024 ↗View →
DYN
DYNE THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
17,825$25.48$454.2K141,184Mar 11, 2024Mar 12, 2024 ↗View →
DYN
DYNE THERAPEUTICS, INC.
PURCHASE
Chief Business Officer
17,825$5.54$98.8K159,009Mar 11, 2024Mar 12, 2024 ↗View →
DYN
DYNE THERAPEUTICS, INC.
SALE
Chief Business Officer
17,825——0Mar 11, 2024Mar 12, 2024 ↗View →
DYN
DYNE THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
1,776$25.71$45.7K139,408Mar 11, 2024Mar 12, 2024 ↗View →
DYN
DYNE THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
34,663$25.46$882.5K196,521Mar 8, 2024Mar 12, 2024 ↗View →
DYN
DYNE THERAPEUTICS, INC.
SALE
Chief Business Officer
3,841———Mar 8, 2024Mar 12, 2024 ↗View →
DYN
DYNE THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
54,648$26.72$1.46M141,873Mar 8, 2024Mar 12, 2024 ↗View →
DYN
DYNE THERAPEUTICS, INC.
PURCHASE
Chief Business Officer
3,841$5.54$21.3K231,184Mar 8, 2024Mar 12, 2024 ↗View →
DYN
DYNE THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
689$27.31$18.8K141,184Mar 8, 2024Mar 12, 2024 ↗View →
DYN
DYNE THERAPEUTICS, INC.
PURCHASE
Chief Business Officer
86,159$5.54$477.3K227,343Mar 8, 2024Mar 12, 2024 ↗View →
DYN
DYNE THERAPEUTICS, INC.
SALE
Chief Business Officer
86,159——12,309Mar 8, 2024Mar 12, 2024 ↗View →
DYN
DYNE THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
2,434$25.85$62.9K141,184Mar 7, 2024Mar 11, 2024 ↗View →
DYN
DYNE THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
1,442$29.70$42.8K143,618Mar 1, 2024Mar 1, 2024 ↗View →
DYN
DYNE THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
8,715$29.06$253.3K145,060Mar 1, 2024Mar 1, 2024 ↗View →
DYN
DYNE THERAPEUTICS, INC.
PURCHASE
Chief Business Officer
24,260$0.73$17.7K167,878Mar 1, 2024Mar 1, 2024 ↗View →
DYN
DYNE THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
14,103$28.25$398.4K153,775Mar 1, 2024Mar 1, 2024 ↗View →
DYN
DYNE THERAPEUTICS, INC.
SALE
Chief Business Officer
24,260——0Mar 1, 2024Mar 1, 2024 ↗View →
DYN
DYNE THERAPEUTICS, INC.
SALE
Chief Business Officer
4,268——24,260Feb 29, 2024Mar 1, 2024 ↗View →
DYN
DYNE THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
4,268$27.50$117.4K143,618Feb 29, 2024Mar 1, 2024 ↗View →
DYN
DYNE THERAPEUTICS, INC.
PURCHASE
Chief Business Officer
4,268$0.73$3.1K147,886Feb 29, 2024Mar 1, 2024 ↗View →
DYN
DYNE THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
19,822$24.52$486.0K143,796Jan 26, 2024Jan 26, 2024 ↗View →
DYN
DYNE THERAPEUTICS, INC.
PURCHASE
Chief Business Officer
20,000$0.73$14.6K163,618Jan 26, 2024Jan 26, 2024 ↗View →
DYN
DYNE THERAPEUTICS, INC.
SALE
Chief Business Officer
20,000——28,528Jan 26, 2024Jan 26, 2024 ↗View →
DYN
DYNE THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
178$25.14$4.5K143,618Jan 26, 2024Jan 26, 2024 ↗View →
DYN
DYNE THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
2,009$18.04$36.2K143,618Jan 4, 2024Jan 4, 2024 ↗View →
DYN
DYNE THERAPEUTICS, INC.
SALE
Chief Business Officer
2,009——48,528Jan 4, 2024Jan 4, 2024 ↗View →
DYN
DYNE THERAPEUTICS, INC.
PURCHASE
Chief Business Officer
2,009$0.73$1.5K145,627Jan 4, 2024Jan 4, 2024 ↗View →
DYN
DYNE THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
7,691$18.34$141.1K153,918Jan 3, 2024Jan 4, 2024 ↗View →
DYN
DYNE THERAPEUTICS, INC.
SALE
Chief Business Officer
17,991——50,537Jan 3, 2024Jan 4, 2024 ↗View →
DYN
DYNE THERAPEUTICS, INC.
PURCHASE
Chief Business Officer
17,991$0.73$13.1K161,609Jan 3, 2024Jan 4, 2024 ↗View →
DYN
DYNE THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
10,300$19.03$196.0K143,618Jan 3, 2024Jan 4, 2024 ↗View →
DYN
DYNE THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
11,900$13.10$155.9K143,618Jan 2, 2024Jan 4, 2024 ↗View →
DYN
DYNE THERAPEUTICS, INC.
SALE
Chief Business Officer
1,245$10.72$13.3K155,518Dec 11, 2023Dec 12, 2023 ↗View →
DYN
DYNE THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
37,445——37,445Nov 15, 2023Nov 16, 2023 ↗View →
DYN
DYNE THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
96,158——156,763Nov 15, 2023Nov 16, 2023 ↗View →
DYN
DYNE THERAPEUTICS, INC.
SALE
Chief Business Officer
1,261$9.41$11.9K60,605Sep 18, 2023Sep 20, 2023 ↗View →
DYN
DYNE THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
1,266$10.41$13.2K61,866Sep 12, 2023Sep 13, 2023 ↗View →
DYN
DYNE THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
35,000——35,000Jul 11, 2023Apr 4, 2024 ↗View →
DYN
DYNE THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
1,259$12.43$15.6K63,132Jun 13, 2023Jun 14, 2023 ↗View →
DYN
DYNE THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
1,000$13.00$13.0K64,391Jun 12, 2023Jun 14, 2023 ↗View →
DYN
DYNE THERAPEUTICS, INC.
SALE
See Remarks
1,209$13.33$16.1K65,391Mar 14, 2023Mar 15, 2023 ↗View →
DYN
DYNE THERAPEUTICS, INC.
SALE
See Remarks
1,000$13.00$13.0K66,600Mar 13, 2023Mar 15, 2023 ↗View →
DYN
DYNE THERAPEUTICS, INC.
SALE
See Remarks
10,000——68,528Jan 18, 2023Jan 23, 2023 ↗View →
DYN
DYNE THERAPEUTICS, INC.
SALE
See Remarks
10,000$14.03$140.3K67,600Jan 18, 2023Jan 23, 2023 ↗View →
DYN
DYNE THERAPEUTICS, INC.
PURCHASE
See Remarks
10,000$0.73$7.3K77,600Jan 18, 2023Jan 23, 2023 ↗View →
DYN
DYNE THERAPEUTICS, INC.
SALE
See Remarks
30,150$11.57$348.8K67,600Jan 9, 2023Jan 11, 2023 ↗View →
DYN
DYNE THERAPEUTICS, INC.
SALE
See Remarks
472$10.87$5.1K97,750Dec 12, 2022Dec 13, 2022 ↗View →
DYN
DYNE THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
63,000——63,000Dec 9, 2022Dec 13, 2022 ↗View →
DYN
DYNE THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
40,000——98,222Dec 9, 2022Dec 13, 2022 ↗View →
DYN
DYNE THERAPEUTICS, INC.
SALE
See Remarks
1,246$13.70$17.1K58,222Sep 20, 2022Sep 21, 2022 ↗View →
DYN
DYNE THERAPEUTICS, INC.
SALE
See Remarks
494$14.05$6.9K59,468Sep 15, 2022Sep 15, 2022 ↗View →
DYN
DYNE THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
21,666——21,666Jul 5, 2022Jul 6, 2022 ↗View →
DYN
DYNE THERAPEUTICS, INC.
SALE
See Remarks
504$4.95$2.5K59,962Jun 14, 2022Jun 15, 2022 ↗View →
DYN
DYNE THERAPEUTICS, INC.
SALE
See Remarks
481$8.73$4.2K60,466Mar 11, 2022Mar 14, 2022 ↗View →
DYN
DYNE THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
25,311——60,947Dec 10, 2021Dec 14, 2021 ↗View →
DYN
DYNE THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
37,967——37,967Dec 10, 2021Dec 14, 2021 ↗View →
DYN
DYNE THERAPEUTICS, INC.
SALE
See Remarks
729$16.11$11.7K35,636Sep 21, 2021Sep 22, 2021 ↗View →
DYN
DYNE THERAPEUTICS, INC.
SALE
See Remarks
545$15.61$8.5K36,365Sep 20, 2021Sep 22, 2021 ↗View →
DYN
DYNE THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
25,000——25,000Jul 10, 2021Jul 13, 2021 ↗View →
DYN
DYNE THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
17,012——36,910Sep 17, 2020Sep 18, 2020 ↗View →
DYN
DYNE THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
52,787——52,787Sep 16, 2020Sep 18, 2020 ↗View →
Other insiders · DYN
Loading peer insiders…
About this filer
CIK 0001824673
ROLE
See Remarks
PRIMARY
DYN
COMPANIES
2
ACTIVE SINCE
Sep 2020
MARKETPEEL · /INSIDER/0001824673DATA · SEC EDGAR · FORM 4 · CONSOLIDATED TAPE
FREE · DAILY · 6 AM ET

The morning brief, before the bell.

One short email. Insider buys, congressional trades, and plain-English analysis.

Feedback